Jubilant Discovery Services Inc., Bedminster, New Jersey, a Jubilant life sciences company, has entered into a drug discovery alliance with Janssen Pharmaceutica N V, Beerse, Belgium. The key objective of the alliance set to span an initial period of 3 years is to deliver preclinical candidates to Janssen in the area of neuroscience.

Under the terms of the alliance agreement, Janssen will transfer ongoing efforts on selected drug discovery targets to Jubilant. The latter would  shall then carry out the research services and deliver preclinical candidates to the former for possible further development and commercialization. In addition to receiving research funding, Jubilant may also be eligible to receive milestones and royalties should Janssen successfully develop and commercialize the candidates.

Commenting on this development, Sri Mosur, CEO & president, Global Drug Discovery & Development, Jubilant said that "The collaboration will utilize Jubilant’s global research network to include our new research facility in the US focused in the area of neuroscience, in addition to our India-based research centres. We look forward to enhancing the research and development efforts at Janssen through this unique and creative alliance in these dynamic times in the industry.”